TABLE 2.
Bacterium | Route of administration of bacteria | Murine model | Training agent | Time between last dose of training agent and bacterial challenge | Survival | Bacterial titers | Histopathological changes | Expt repeated | Notes | Reference |
---|---|---|---|---|---|---|---|---|---|---|
Staphylococcus aureus | i.v. | 129 Sv mice | β-glucan i.v. | 4 days | ↑ | + | 54 | |||
i.v. | AKR/J mice | β-glucan i.v. | 4 days | ↑ | ↓ renal necrosis | − | 55 | |||
i.v. | C57BL/6J mice | Zymosan i.p. | 3 days | ↑ | ↓ in blood | − | 58 | |||
i.v. | CD2F1 mice | PCA-2 yeast cells i.v. | 2 wks | ↑ | − | 56 | ||||
i.v. | CDF1 mice | BCG i.p. | 2 wks | ↑ | − | 57 | ||||
Bacteria-laden K wire in a bone | C57BL/6 mice | Zymosan i.v. | 2 wks | ↓ in joint | − | Similar results with LPS i.v. as training agent and/or when challenged with i.v. S. aureus | 65 | |||
s.c. in both flanks | Rag1−/− mice in BALB/c background | S. aureus s.c. in right flank | 6 wks | ↓ in skin | ↓ size of abscesses | − | 68 | |||
Mycobacterium tuberculosis | i.n. | BALB/c mice | β-glucan i.p. | 4 days | ↑ | ↓ in lung | − | 60 | ||
Listeria monocytogenes | i.v. | C57BL/6J mice | Zymosan i.p. | 3 days | ↑ | ↓ in blood, spleen, liver, and kidney | + | 58 | ||
+ | 61 | |||||||||
i.p. | C57BL/6J mice | γHV68 i.n. | 4 wks | ↑ | ↓ in spleen and liver | + | 61 | |||
Yersinia pestis | i.n. | C57BL/6J mice | γHV68 i.n. | 4 wks | ↓ in spleen and lungs | + | 61 | |||
Streptococcus pneumoniae | i.n. | C57BL/6J mice | MTBVAC s.c. | 9 wks | ↑ | ↓ in blood | + | 62 | ||
i.t. | BALB/c mice | Respiratory adenovirus infection i.n. | 4 wks | ↑ | ↓ in lungs and spleen | + | 63 | |||
Escherichia coli | Bacteria-laden suture in muscle | Swiss Webster mice | BCG s.c. | 13 days | ↓ at site of challenge | + | 66 | |||
Bacteria-laden K wire in a bone | C57BL/6 mice | Zymosan i.v. | 2 wks | ↓ in joint | − | Similar results with LPS i.v. as training agent and/or when challenged with i.v. E. coli | 65 | |||
i.p. | C57BL/6J mice | Zymosan i.p. | 3 days | ↑ | − | 58 | ||||
Pseudomonas aeruginosa | i.n. | C57BL/6J mice | Zymosan i.p. | 3 days | ↑ | − | 58 | |||
Bacteria-laden K wire in a bone | C57BL/6 mice | Zymosan i.v. | 2 wks | ↓ in joint | − | Similar results with LPS i.v. as training agent and/or when challenged with i.v. P. aeruginosa | 65 | |||
Streptococcus pyogenes | Bacteria-laden K wire in a bone | C57BL/6 mice | Zymosan i.v. | 2 wks | ↓ in joint | − | Similar results with LPS i.v. as training agent and/or when challenged with i.v. S. pyogenes | 65 | ||
Enterococcus faecalis | Bacteria-laden K wire in a bone | C57BL/6 mice | Zymosan i.v. | 2 wks | ↓ in joint | − | Similar results with LPS i.v. as training agent and/or when challenged with i.v. E. faecalis | 65 | ||
Klebsiella pneumoniae | Bacteria-laden suture in muscle | Swiss Webster mice | MDP s.c. | 1 day | ↓ in blood | − | 64 |
BCG, bacillus Calmette-Guérin; CpG ODN, synthetic oligodeoxynucleotides expressing CpG motif; i.t., intratracheally; i.n., intranasally; i.p., intraperitoneally; i.v., intravenously; LPS, lipopolysaccharide; MDP, muramyl dipeptide; s.c., subcutaneously; ↑, significantly increased; ↓, significantly decreased; −, not mentioned; +, performed in study.